A modified intein for temperature sensitive applications
Controlled Protein Release Over a Broad Range of Temperatures
In the biotechnology field, the demand for efficient protein purification methods and innovative drug delivery solutions is ever-growing. Researchers and companies require technologies that can streamline the purification process, ensuring high yields and purity, while offering versatile applications. Inteins have demonstrated their potential in these areas, but the issue of premature cleavage during expression in microbial cells presents a significant hurdle. There's a pressing need for a solution that overcomes this limitation and enhances the performance of inteins in various applications.
The I-12 and I-29 variants of the ΔI-CM mini intein are groundbreaking innovations designed to address the premature cleavage issue while maintaining efficient cleavage under optimized conditions. These mutant inteins are engineered to significantly reduce premature cleavage during protein expression in microbial cells, making them invaluable for protein purification through a self-removing tag method and for drug delivery applications. Their unique mutations offer a novel approach to intein technology, enhancing its utility in diverse applications as well as allowing for controlled protein release over a broad range of temperatures.
In summary, the I-12 and I-29 mutant inteins represent a pioneering technology that addresses a critical challenge in protein purification and offers promising solutions in drug delivery applications. Their ability to reduce premature cleavage while ensuring efficient cleavage under optimized conditions makes them a game-changing asset for researchers and companies in the biotechnology and pharmaceutical industries.